The Judicial Panel for Multidistrict Litigation has authorized the transfer of dozens of lawsuits over the diabetes drug Invokana to a New Jersey federal court, centralizing the litigation.
In an order issued Dec. 8, the panel approved the request to centralize the cases in the U.S. District Court for the District of New Jersey by plaintiffs in 29 cases already filed there. In its entirety, the combined litigation consists of 55 cases against drugmaker Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
